Delcath Systems (DCTH) Stock Forecast & Price Target

Delcath Systems Inc. has demonstrated substantial growth in its Hepzato procedure volume, increasing by 140% in 2025, indicative of enhanced physician utilization and commercial traction. The company reported a year-end cash balance of $91.0 million, reflecting operational efficiency and solid financial health. With ongoing initiatives aimed at boosting referrals and expanding into new regions, coupled with expectations for a salesforce expansion, the outlook for sustained Hepzato adoption in 2026 appears particularly promising.

Delcath Systems Inc. has lowered its full-year revenue expectations to $83M-$85M from a prior forecast of $93M-$96M, primarily due to a slowdown in new site activations and a decrease in new patient starts influenced by summer seasonality and competitive clinical trials. The company anticipates quarterly gross margins of 85-87%, slightly improved from previous estimates, but still faces challenges stemming from a ~23% discount under the Medicaid National Drug Rebate Agreement Program. Furthermore, Delcath remains cash flow negative, raising concerns about its ability to generate projected revenues and sustain operations in a competitive environment.